1604. Cost-Effectiveness of Ceftazidime-Avibactam for Patients with Hospital-Acquired Pneumonia Caused by Multi-Drug Resistant Enterobacteriaceae or Pseudomonas in China
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1784
Abstract: To estimate the cost-effectiveness of ceftazidime-avibactam (CAZ-AVI) for the treatment of hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) caused by multi-drug resistant enterobacteriaceae (MDRE) or MDR pseudomonas aeruginosa (MDRPA) in China. A previously published patient-level… read more here.
Keywords: caz avi; effectiveness ceftazidime; pfizer; cost ... See more keywords